| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Jiangsu Aidea Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥7.90 |
| 52 Week High | CN¥17.40 |
| 52 Week Low | CN¥6.58 |
| Beta | 0.36 |
| 11 Month Change | -4.24% |
| 3 Month Change | -17.88% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -35.19% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688488 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 18.6% | 16.7% | 15.4% |
| 1Y | n/a | -18.4% | -7.9% |
Return vs Industry: Insufficient data to determine how 688488 performed against the CN Biotechs industry.
Return vs Market: Insufficient data to determine how 688488 performed against the CN Market.
Price Volatility
| 688488 volatility | |
|---|---|
| 688488 Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 6.0% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in CN Market | 8.5% |
| 10% least volatile stocks in CN Market | 3.9% |
Stable Share Price: 688488's share price has been volatile over the past 3 months.
Volatility Over Time: 688488's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 491 | Jie Zhang | www.aidea.com.cn |
Jiangsu Aidea Pharmaceutical Co., Ltd. develops, produces, and sells pharmaceutical products. It offers ainuovirine tablets; urinary protein products, including crude product/intermediate of ulinastatin, urinary kallidinogenase, and urokinase; sennae folium granules; and HIV diagnostic equipment and reagents. The company was founded in 2009 and is headquartered in Yangzhou, China.
Jiangsu Aidea Pharmaceutical Co., Ltd. Fundamentals Summary
| 688488 fundamental statistics | |
|---|---|
| Market cap | CN¥3.32b |
| Earnings (TTM) | -CN¥111.90m |
| Revenue (TTM) | CN¥353.69m |
9.4x
P/S Ratio-29.7x
P/E RatioIs 688488 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688488 income statement (TTM) | |
|---|---|
| Revenue | CN¥353.69m |
| Cost of Revenue | CN¥212.26m |
| Gross Profit | CN¥141.43m |
| Other Expenses | CN¥253.33m |
| Earnings | -CN¥111.90m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.27 |
| Gross Margin | 39.99% |
| Net Profit Margin | -31.64% |
| Debt/Equity Ratio | 36.5% |
How did 688488 perform over the long term?
See historical performance and comparison